ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 Post author:Marianne Duparc Post published:March 11, 2022 Post category:Newsroom ERYTECH Pharma (Nasdaq & Euronext: ERYP) provided a business update and an update on its cash position at the end of December 2021. You Might Also Like ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F April 24, 2018 ERYTECH to Participate in the Upcoming January Virtual Investor Conferences January 3, 2022 ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F April 24, 2018
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014